A new drug that could cut down on deadly autoimmune diseases has been approved by the U.S. Food and Drug Administration (FDA). The drug, known as Inflectra, was developed by Celltrion and is expected to be co-marketed by both Celltrion and Pfizer. Inflectra is a “biosimilar†version of Remicade, which is already used by doctors …